MedDataX Logo

Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

NCT ID: NCT04690920

Last Updated: 2020-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-23

Study Completion Date

2020-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corona Virus Disease 2019 (COVID-19)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

corona virus disease 2019 (COVID-19) Tocilizumab Remdesivir Interleukin receptor-6, glycoprotein-130 receptor blocker

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Group Type NO_INTERVENTION

No interventions assigned to this group

Tocilizumab

Group Type EXPERIMENTAL

Tocilizumab

Intervention Type DRUG

Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Remdesivir

Group Type EXPERIMENTAL

Tocilizumab

Intervention Type DRUG

Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Standard Treatment

Group Type ACTIVE_COMPARATOR

Tocilizumab

Intervention Type DRUG

Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tocilizumab

Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Remdesivir Standard treatment with Antibiotic, oxygen, Vitamin C, Statins No treatment is given to control group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy

Exclusion Criteria

Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Lahore

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Muhammad Mansoor Hafeez

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arif Malik, PhD

Role: STUDY_DIRECTOR

University of Lahore

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Lahore

Lahore, Punjab Province, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UOL/IMBB/2020/118

Identifier Type: -

Identifier Source: org_study_id